Quanterix to Present at Cowen’s 44th Annual Health Care Conference

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen’s 44th Annual Health Care Conference. Quanterix’s session will take place on Monday, March 4, 2024, at 12:50 p.m. EST and will be made available to attendees and, via webcast, the general public. In addition to the session, Quanterix will also host one-on-one meetings with institutional investors during the conference.

Cowen’s 44th Annual Health Care Conference will take place March 4 - 6, 2024, in Boston, MA. The conference incorporates presentations, fireside chats and panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.

Webcast Information
To access the live audio webcast of Quanterix’s presentation at the conference, please visit: https://wsw.com/webcast/cowen154/qtrx/2067466. Quanterix’s session will take place on Monday, March 4, 2024, at 12:50 p.m. EST.

Replays of the presentation will be available for a limited period following the conference. The presentation will also be made available through the Investor Relations section of Quanterix’s website.

To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix’s Simoa® technology, visit: www.quanterix.com/simoa-technology/.

About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,700 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240223277311/en/

Media Contact:
PAN Communications
Maya Nimnicht
510-334-6273
[email protected]

Investor Relations Contact:
Amy Achorn
(978) 488-1854
[email protected]

Source: Quanterix Corporation

You May Also Be Interested In

• Socure and Aeropay Reduce Onboarding Friction to Only a Phone Number and Two Clicks
• PwC Middle East and Axelera AI Collaborate to Help Regional Organisations Turn AI Ambition Into Measurable Outcomes
• National Foundation for Credit Counseling Recognizes Three Inspiring Individuals Who Overcame Debt Challenges to Achieve Financial Stability